Annexon Biosciences is a clinical-stage biopharmaceutical company headquartered in Brisbane, California, focused on developing novel therapeutics that inhibit the complement cascade to treat neurodegenerative diseases and autoimmune conditions. The company's lead asset targets C1q, the initiating molecule of the classical complement pathway, which plays a critical role in synaptic elimination and neuroinflammation[1].
Annexon was founded in 2011 and went public in 2020 (NASDAQ: ANNX). The company leverages its understanding of complement biology to develop treatments for conditions where complement-mediated inflammation contributes to disease pathology.
| Drug Candidate | Indication | Stage | Mechanism | Notes |
|---|---|---|---|---|
| ANX005 | Guillain-Barré Syndrome | Phase 3 | Anti-C1q mAb | Received FDA Fast Track designation |
| ANX005 | Huntington's Disease | Phase 2 | Anti-C1q mAb | Targeting complement-mediated neurodegeneration |
| ANX007 | Geographic Atrophy (GA) | Phase 2 | Anti-C1q Fab | Intravitreal formulation |
| ANX010 | Amyotrophic Lateral Sclerosis (ALS) | Preclinical | Anti-C1q mAb | Pipeline expansion |
Huntington's disease (HD) is a fatal genetic neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. Annexon's approach targets C1q, which is elevated in HD brains and contributes to synaptic dysfunction and neuronal loss[2].
The Phase 2 trial of ANX005 in HD patients evaluated safety and biomarkers of complement activation. The company reported that ANX005 was generally well-tolerated and showed evidence of target engagement.
Guillain-Barré Syndrome (GBS) is an acute autoimmune disorder where the immune system attacks peripheral nerves. ANX005 has been evaluated in a Phase 1b/2 study showing promising results in reducing complement activation markers[3].
Geographic atrophy is an advanced form of age-related macular degeneration (AMD) leading to irreversible vision loss. ANX007 is being developed as an intravitreal therapy to inhibit C1q-mediated inflammation in the retina[4].
Annexon's platform is built on the understanding that the complement system, particularly C1q, plays a dual role in immune surveillance and pathological inflammation. In neurodegenerative diseases, excessive C1q activation leads to:
By inhibiting C1q, Annexon's therapeutics aim to protect synapses and preserve neuronal function[5].
Annexon has collaborated with academic institutions and has received grant funding from the Huntington's Disease Society of America and other organizations to support its clinical programs.